The aim of the MARCAR project is to identify early biological indicators ("biomarkers") that can be used to predict the effects of Non Genotoxic Carcinogens (NGC) .
The MARCAR project is a 5 year project funded under the Innovative Medicines Initiative Joint Undertaking
What is MARCAR?
The main impact of the MARCAR project will be to establish, for the first time, proof of concept that early biomarkers can reliably and robustly predict later cancer development. Validation of the biomarkers identified in the initial experiments will be a key stage in the project as early biomarkers of carcinogenicity would be immensely valuable in preclinical development of new drug compounds.